Müllerian-Inhibiting Substance/Anti-Müllerian Hormone as a Predictor of Preterm Birth in Polycystic Ovary Syndrome | Zendy

Jennifer Y. Hsu | Zendy; Kaitlyn E. James | Zendy; Charles L. Bormann | Zendy; Patricia K. Donahoe | Zendy; David Pépin | Zendy; Mary E. Sabatini | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Müllerian-Inhibiting Substance/Anti-Müllerian Hormone as a Predictor of Preterm Birth in Polycystic Ovary Syndrome

Author(s) -

Jennifer Y. Hsu,

Kaitlyn E. James,

Charles L. Bormann,

Patricia K. Donahoe,

David Pépin,

Mary E. Sabatini

Publication year - 2018

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2018-01320

Subject(s) - anti müllerian hormone , medicine , polycystic ovary , obstetrics , ovarian reserve , infertility , gynecology , pregnancy , miscarriage , in vitro fertilisation , hormone , insulin resistance , obesity , biology , genetics

There is increasing evidence for Müllerian-inhibiting substance (MIS)/anti-Müllerian hormone (AMH) physiologic activity in the human uterus, so it is relevant to study how MIS/AMH levels impact pregnancy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research